---
title: "Fudan-Zhangjiang Places RMB150 Million in Low-Risk Bank of China Structured Deposit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271635970.md"
description: "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB150 million in a low-risk structured deposit with Bank of China, utilizing idle funds from its A-share public offering. The 84-day deposit, linked to the AUD/USD rate, offers a floating annualized return of 0.35% to 1.6539%. This transaction is disclosable under Hong Kong listing rules, reflecting the company's conservative treasury management strategy."
datetime: "2026-01-06T10:08:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271635970.md)
  - [en](https://longbridge.com/en/news/271635970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271635970.md)
---

# Fudan-Zhangjiang Places RMB150 Million in Low-Risk Bank of China Structured Deposit

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has shared an update.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has entered into an agreement with Bank of China to subscribe to a principal-guaranteed, low-risk structured deposit product for RMB150 million, using temporarily idle proceeds from its A-share public offering. The 84-day deposit, linked to the AUD/USD central parity spot rate, offers a floating annualized return between 0.35% and 1.6539%, and qualifies as a disclosable transaction under Hong Kong listing rules, requiring reporting and announcement but not shareholder approval, highlighting the company’s conservative approach to short-term treasury management and optimization of excess capital.

**More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co**

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. is a Hong Kong-listed biopharmaceutical company that raises capital through public share issuances and manages its funds using financial instruments available in the domestic banking market.

**Average Trading Volume:** 1,946,421

**Current Market Cap:** HK$965M

### Related Stocks

- [01349.HK](https://longbridge.com/en/quote/01349.HK.md)
- [688505.CN](https://longbridge.com/en/quote/688505.CN.md)

## Related News & Research

- [Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits](https://longbridge.com/en/news/271770137.md)
- [Headway Launches $150 No Deposit Bonus](https://longbridge.com/en/news/286344490.md)
- [Ambertech Insiders Still AU$98k Away From Original Investment Value](https://longbridge.com/en/news/286961994.md)
- [Shaw and Partners Keeps Their Buy Rating on Southern Cross Gold Consolidated Ltd. Chees Depository Interest Repr 1 shs (SX2)](https://longbridge.com/en/news/286979340.md)
- [Bell Potter Sticks to Their Buy Rating for WA1 Resources Ltd (WA1)](https://longbridge.com/en/news/286490349.md)